Abstract
Autosomal dominant polycystic kidney disease (ADPKD), often caused by mutations in the PKD1 gene, is associated with life-threatening vascular abnormalities that are commonly attributed to the frequent occurrence of hypertension. A previously reported targeted mutation of the mouse homologue of PKD1 was not associated with vascular fragility, leading to the suggestion that the vascular lesion may be of a secondary nature. Here we demonstrate a primary role of PKD1 mutations in vascular fragility. Mouse embryos homozygous for the mutant allele (Pkd1L) exhibit s.c. edema, vascular leaks, and rupture of blood vessels, culminating in embryonic lethality at embryonic day 15.5. Kidney and pancreatic ductal cysts are present. The Pkd1-encoded protein, mouse polycystin 1, was detected in normal endothelium and the surrounding vascular smooth muscle cells. These data reveal a requisite role for polycystin 1 in maintaining the structural integrity of the vasculature as well as epithelium and suggest that the nature of the PKD1 mutation contributes to the phenotypic variance in ADPKD.
Keywords: homologous recombination, angiogenesis, tight junctions, polycystic kidney disease
Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic disease in humans, with a frequency ranging from 1:400 to 1:1,000 persons (1). The cardinal feature of ADPKD is the formation of cysts in both kidneys (2), which originate from fewer than 1% of all nephrons (3), and lead over time to progressive destruction of normal renal tissue and end-stage kidney failure in more than 50% of patients. There is also a high prevalence of extrarenal manifestations in ADPKD. These consist of cyst formation in other ductal organs and vascular abnormalities including aneurysms in the cerebral and coronary blood vessels (4). Intracranial aneurysms are observed in approximately 10% of asymptomatic adults with ADPKD (5, 6), and the aneurysms' sudden rupture is responsible for death in up to 20% of the cases (7). Clustering of intracranial aneurysms has been described in several ADPKD families, with the incidence rising to 25% in the asymptomatic patients (5, 6). Furthermore, retrospective analysis of renal tissue from patients with ADPKD reveals sclerotic vascular changes present early in the course of the disease, which may contribute to the progressive loss of renal function (8). The vascular abnormalities seen in ADPKD commonly are attributed to hypertension that frequently complicates the course of ADPKD.
In 85–95% of the cases of ADPKD, the disease is caused by heterogeneous mutations in the PKD1 gene. PKD1 encodes polycystin 1, an 11-pass membrane protein with a large extracellular region composed of a unique compilation of potential adhesion and protein–protein interaction domains (9, 10). In ≈5–15% of cases, a second gene (PKD2) is responsible, and the disease is generally milder. PKD2 encodes polycystin 2, a six-pass membrane protein with homology to voltage-activated calcium channels (11, 12). In a small number of families, a third yet-to-be-characterized gene has been implicated (13). Polycystins are expressed in epithelia (14–17). Polycystin 1 also has been detected in endothelial and vascular smooth muscle cells (18, 19). Polycystin 1 has been found at cell–cell junctions in endothelial (19) and epithelial (20) cell monolayers. Mouse models with targeted mutations in PKD1 (21) and PKD2 (22) develop renal, pancreatic, and liver cysts, but not the vascular fragility seen in humans. This finding implied that the vascular abnormalities seen in ADPKD may be secondary in nature.
In this paper, we show that mice homozygous for a targeted mutation in the mouse homologue of PKD1 die in utero between 14.5 and 15.5 days postcoitum [embryonic day (E) 14.5–15.5], most likely the result of massive hemorrhage. At earlier time points (E12.5–13.5), s.c. edema and focal vascular leaks and hemorrhage are present. Focal hemorrhage often is seen in tissues undergoing angiogenesis. Renal and pancreatic cysts are seen beginning at E13.5. Immunostaining revealed that wild-type (WT) as well as mutant polycystin 1 are expressed in epithelium, endothelium, and vascular smooth muscle. Taken together, these findings indicate that phenotypic variability in ADPKD is caused in part by the nature of the PKD1 mutation, and that polycystin 1 is essential for maintaining the integrity of blood vessels, in addition to mature epithelium.
Methods
Generation of Pkd1 Knockout Mice.
We isolated a mouse genomic clone containing the mouse PKD1 homologue (Pkd1) by screening a library with the human cDNA probe 3A3 (9). The mouse genomic fragment was used to isolate a larger murine (strain 129sv) Bac clone. A 6-kb EcoRI–XbaI and a 4-kb NotI-restricted murine Pkd1 fragments were generated by PCR, confirmed by sequencing, and cloned on either side of the neo gene in the double selection plasmid pPNT (which contains a neomycin phosphotransferase, neo, controlled by the phosphoglycerol kinase promoter for positive selection and a herpes simplex virus thymidine kinase, HSVTK, gene for negative selection). The neo cassette was placed in the opposite transcriptional orientation to the Pkd1 gene. In the resulting mutant allele, portions of exons 43 and 45 and all of exon 44 are replaced by the neo cassette, and a stop codon was introduced at the end of the remaining segment of exon 43. The J1 line of embryonic stem (ES) cells (23) was grown on subconfluent γ-irradiated embryonic fibroblasts (24) and used for transfections. The linearized recombination vector was electroporated into J1 ES cells. Two independent ES clones (#130 and #282) heterozygous for the mutant allele (Pkd1L) were identified through probing KpnI-digested DNA with the 5′ cDNA probe and were injected into blastocysts from C57 black mice. Blastocysts then were placed into pseudopregnant female mice. Chimeric mice were used for breeding with WT C57 black mice. The male chimeras were mated with normal females to generate heterozygous mice Pkd1+/L. WT, Pkd1+/L, and Pkd1L/L embryos and mice were identified by Southern blot analysis of KpnI- or XhoI-restricted yolk sac and tail DNA, respectively.
In Vivo Assessment of Vascular Leak.
E12.5 embryos were maintained in PBS and positioned in an agarose trough for injection. Micropipets filled with dye solution [0.5% lysinated FITC-dextran (70 kDa; Molecular Probes), 0.2% trypan blue in PBS containing 1 mM CaCl2 and 1 mM MgCl2] were introduced into the anterior cardinal vein. A total volume of 1–2 μl of dye solution was injected over a period of 5–10 min. Successful introduction of dye was monitored visually by using trypan blue. All embryos had active circulation at the time of injection as assessed by blood flow in the anterior cardinal vein. Immediately after injection, embryos were fixed in 4% paraformaldehyde/PBS. After dehydration and embedding in glycol methacrylate (JB-4; Polysciences), 4-μm sections were cut on glass knives and mounted in vectashield (Vector Laboratories) for fluorescence microscopy.
Antibody Preparation.
Specific anti-human polycystin 1 polyclonal antibodies against three different glutathione S-transferase-fusion proteins were produced in rabbits (19). Fusion proteins FP-LRR (leucine-rich repeats) (residues 27–360), FP-BD3 (residues 4097–4302) (19), and FP-L2 (containing part of the receptor for egg jelly-like (REJ) domain of polycystin-1, residues 2714–3074) were generated by using pGEX vectors (Amersham Pharmacia) and purified. The antipeptide antibodies AP-1 and AP-2, directed, respectively, against regions in the REJ and cytoplasmic C-terminal domains of human polycystin 1 have been described (16).
Embryo Tissue Preparation and Immunostaining.
Embryos were fixed overnight at 4°C in 4% paraformaldehyde/PBS immediately after harvesting. WT, Pkd1+/L, and Pkd1L/L embryos were embedded in paraffin, sectioned into 5-μm thick sections, and stained with hematoxylin and eosin. Sections were mounted in Permount (Fisher) and observed by using a light microscope. For immunostaining, a standard immunoperoxidase protocol (Vectastain ABC kit, Vector Laboratories) was used. Paraffin sections were deparaffinized in xylene, rehydrated in graded ethanol, rinsed in tap water, and treated with trypsin (50 μg/ml in PBS), before a 2-min microwave heating in citrate buffer, pH 6.0 (18). After blocking with 2% goat serum, sections were incubated with the primary antibodies (2 μg/ml) for 1 hr at room temperature, rinsed in PBS, incubated with biotinylated goat anti-rabbit secondary antibodies, rinsed, then incubated with diaminobenzidine as a chromogen, counterstained with hematoxylin and eosin, and examined by light microscopy.
Results
Mice Homozygous for the Pkd1L Allele Die in Utero.
The targeted strategy for Pkd1 and genotype analysis of ES clones and mice are summarized in Fig. 1 A–D. Of 184 recombinant ES cell clones screened, four were heterozygous for the mutant Pkd1L allele by Southern blotting. Two independent clones (#130 and #282) produced ≈80% and 100% chimeric mice, respectively. Chimeras were crossed with WT C57BL/6 mouse strain. Clone #130-F2 progeny were derived from six females. Genotyping showed 11 WT, 24 Pkd1+/L, and no Pkd1L/L animals. Clone #282-F2 progeny were derived from seven females, and genotyping revealed 16 WT, 29 Pkd1+/L, and again no Pkd1L/l animals. Most of the phenotypic analyses were performed with the #282-derived mouse line, but identical results also were obtained with the #130-derived line (Table 1). The heterozygous F1 and F2 mice, up to 7 months of age, were apparently normal and fertile. The lack of viable Pkd1L/L newborns from Pkd1+/L crossings, even though the ratio of WT to Pkd1+/L offspring was normal, suggests that homozygosity for the Pkd1L allele is embryonically lethal. Northern blot of total RNA derived from WT, Pkd1+/L, and Pkd1L/L mice revealed that the mutant transcript (≈15.4 kb) is expressed in heterozygous and homozygous embryos (Fig. 1E), as is often the case in ADPKD. Probing the same Northern blot with a cDNA encoding the neo gene showed that the probe hybridized to the 15.4-kb species but not to WT, indicating that the mutant mRNA, contains the introduced neo construct, which accounts for its slower mobility. The introduced recombination did not affect the integrity of the adjacent tuberous sclerosis 2 (TSC2) gene, defects of which are known to contribute to the severity of cystic disease in humans (9). This is reflected by the normal size and abundance of TSC2 mRNA (Fig. 1G).
Table 1.
Stage | Pkd1+/+ | Pkd1+/L | Pkd1L/L | ND* | Total |
---|---|---|---|---|---|
282 line | |||||
E11.5 | 11 | 18 | 7 (0)† | 0 | 36 |
E12.5 | 12 | 21 | 9 (3) | 2 | 43 |
E13.5 | 15 | 17 | 12 (7) | 1 | 55 |
E14.5 | 17 | 23 | 14 (8) | 2 | 56 |
E15.5 | 12 | 19 | 9 (7) | 1 | 41 |
E16.5 | 10 | 18 | 0 | 0 | 28 |
E17.5 | 6 | 11 | 0 | 0 | 17 |
Weanling | 16 | 29 | 0 | 0 | 45 |
130 line | |||||
E11.5 | 7 | 14 | 5 (0)† | 0 | 26 |
E12.5 | 10 | 14 | 5 (2) | 1 | 30 |
E13.5 | 6 | 15 | 8 (4) | 1 | 29 |
E14.5 | 12 | 18 | 7 (3) | 2 | 39 |
E15.5 | 8 | 14 | 6 (5) | 1 | 29 |
E16.5 | 6 | 10 | 0 | 0 | 16 |
E17.5 | 5 | 9 | 0 | 0 | 14 |
Weanling | 11 | 24 | 0 | 0 | 35 |
*ND, genotype not determined.
† The number of hemorrhagic phenotype is indicated in parentheses among homozygous mutants. All homozygous mutants had gross edema at every gestational age examined beyond E13.5.
To determine the time at which lethality occurs, embryos from F1 intercrosses were examined at different developmental stages. Analysis of F2 embryos at midgestation showed that until E12.0 there were no gross morphological differences between Pkd1L/L and their Pkd1+/L littermates (not shown). In contrast, by E12.5, s.c. edema and small hemorrhages were observed in 35% (five of 14) of the Pkd1L/L embryos from both lines (Fig. 2, Table 1). By day E15.5, most Pkd1L/L embryos had died, exhibiting extensive hemorrhage and diffuse edema (Fig. 2). No viable Pkd1L/L embryos were found at E16.5 or later. These findings suggest that a vascular defect in Pkd1L/L embryos results in edema formation, leading to frank hemorrhage and lethality by E15.5.
Vascular Leak and Hemorrhage in Pkd1L/L Embryos.
Histological analysis of tissue sections from Pkd1L/L at E13.5 showed localized areas of hemorrhage in multiple regions of the embryo such as the neck (Fig. 3A), skin (Fig. 3B), and brain (see below). In skin tissue with no frank hemorrhage, red blood cells were seen traversing apparently intact vascular endothelium at cell–cell junctions (Fig. 3B). Microinjection of fluorescent dextran (molecular mass 70 kDa) into the anterior cardinal vein of live WT and mutant E13.5 embryos revealed that while the tracer remained in the intravascular compartment in WT animals, it extravasated to the basolateral regions of endothelium and into the extravascular interstitium at distant sites (Fig. 3 C–F). The cell–cell junctions at apparently normal sites in Pkd1L/L embryos were well formed as judged by electron microscopy (data not shown). There were no gross histologic abnormalities in the heart or lungs.
Cyst Formation in Pkd1L/L Mouse Embryos.
Renal and pancreatic cysts were observed at E14.5 in Pkd1L/L embryos (Fig. 3 H and I). In the kidneys, they first appeared as multifocal microscopic dilations of well-developed renal glomerular and tubular structures. Earlier stages of nephrogenesis (mesenchymal condensation, epithelialization) were unaffected. The lesion in the pancreas was again focal and manifested as dilation of pancreatic ducts; Acini appeared normal. No cysts were observed in the liver, as also was observed by Lu et al. (21) in another mouse model of ADPKD caused by a different mutation in Pkd1. Liver cysts were detected in PKD2 knockout mice ranging in age from 1 to 25 weeks (22). The lack of liver cysts in the two Pkd1 models suggests that liver cyst formation may require a longer time or is influenced by the nature of the mutation.
WT and Mutant Polycystin 1 Are Expressed in Endothelium and Smooth Muscle.
As shown in Fig. 4, immunostaining with anti-LRR antibody showed that polycystin 1 was expressed in capillary and small vessel endothelium in both WT and mutant at E14.5 embryos (Fig. 4 A and B). It was not detected in endothelium of major vessels in WT and mutant animals (data not shown). Polycystin 1 was detected in smooth muscle of blood vessels (Fig. 4 A and B), skeletal muscle, and the gut (not shown). Very similar patterns of staining of polycystin 1 were observed by using the anti-receptor for egg jelly-like domain antibody (data not shown). WT and mutant polycystin 1 also were expressed in developing nephrons (Fig. 4 C and E), as we previously reported (16), and in pancreatic ductal epithelium by using anti-LRR (data not shown). The antibody staining pattern was abolished in the presence of a 20-fold molar excess of the immunogen (Fig. 4 D and F). The anticytoplasmic tail antibodies BD3 and AP2 and AP1 did not react reproducibly with WT mouse embryos (not shown).
Discussion
The major finding in this paper is that a targeted mutation in Pkd1 produces embryonic lethality at E15.5 in homozygous mice, secondary to vascular leaks and massive hemorrhage. Renal and pancreatic cysts are seen, as has been previously noted in mice homozygous for a different allele, Pkd1Δ34 (21). The vascular lesion reflects a crucial and direct role of polycystin 1 in the vasculature, as the WT protein was readily detected in endothelium and the underlying vascular smooth muscle cells. The major axial vessels such as the aorta, formed by vasculogenesis (25), appear normal in the Pkd1L/L embryos. Involvement of blood vessels from brain, skin, and limb buds in the Pkd1L/L embryos, which develop by angiogenesis (26), suggest that polycystin 1 is required for the maturation and/or stability of angiogenically derived blood vessels, in addition to its role in maintaining the structural integrity of ductal epithelium.
In a previous study, Lu et al. (21) found that mice homozygous for a frameshift mutation in Pkd1, Pkd1Δ34, display massive renal and pancreatic cysts, with secondary pulmonary hypoplasia and perinatal mortality. Edema also has been described in these mice, but no vascular lesions were reported. It may appear counterintuitive that the L3946* mutant polycystin 1 (Fig. 1H), which is 478 aa longer than the one encoded by the frameshift Pkd1Δ34 mutant (21), should produce a more severe phenotype as judged by embryonic lethality at E15.5 and display a major vascular phenotype. The fact that embryos generated from two independent recombinant ES cell lines exhibited the same phenotype argues against an aberrant insertion of the mutant gene and/or a functionally relevant recombination event. The presence of a normal-sized TSC2 mRNA argues against an unintended recombination in the 3′ region of Pkd1 impairing the TSC2 gene. Hybridization of the mutant 15.5-kb mRNA with the neo probe confirms that a mutant form of Pkd1 was produced. A genetic background effect is also unlikely, because our chimeric mice were crossed with C57BL/6 mice to produce the Pkd1+/L progeny, as in the case of some of the mutant mice generated by Lu et al. (21). The present data therefore suggest that the longer form of mutant polycystin 1 is responsible for the more severe phenotype. There are other precedents where longer forms of a mutant protein can produce a more severe phenotype than shorter or even null versions. CFTR (cystic fibrosis transmembrane conductance regulator) (27) and WT1 (28) are two such examples. The developmental effects of a loss of WT1 for example are in general less severe than point mutations affecting its DNA binding domain (28).
The L3946* mutant contains two intracellular, two extracellular loops, and five transmembrane segments that all are lacking in the mutant encoded by Pkd1Δ34 allele (21). This region is highly conserved in human, mouse, and fish polycystin 1, in particular in loop 3. It is likely that the differences in disease phenotype and severity between Pkd1L/L and Pkd1Δ34/Δ34 mice may be related to the level of expression and/or nature of the respective mutant protein. Both mutant proteins are transcribed, as judged by Northern blots or PCR analysis. It has not yet been determined whether the pkd1Δ34 allele encodes a stable protein. The present data indicate that the protein encoded by L3946* is expressed in homozygous mutants, in the same tissues, and in a pattern that is indistinguishable histologically from that of the WT protein. We speculate that the expressed L3946* polycystin 1 disrupts the normal maturation and/or structural integrity of mature vessels and ductal epithelia in homozygous embryos. Haplo insufficiency in this case is compatible with a normal vascular (and epithelial) phenotype at least up to 7 months of age. A recent correspondence finds that heterozygotes at 16 months of age or older eventually do develop renal cysts, (29). Whether our heterozygote animals will display a cystic phenotype at perhaps an earlier age will be examined.
Expression of polycystin 1 in vascular smooth muscle cells and in endothelia has been previously reported (18, 19). Polycystin 1 also has been detected at intercellular junctions in cultured human umbilical vein endothelium (19), and we found that polycystin 1 is coexpressed with the junctional protein ZO1, a member of the MAGUK (membrane-associated guanylate kinase) protein family, in adult rat tubular epithelium (unpublished observations). The expression of polycystin 1 in the above tissues may account for the observed vascular defect in Pkd1L/L mice. Reciprocal cross-talk between endothelium and surrounding mesenchyme is crucial in the normal assembly of a blood vessel structure. Binding of mesenchymally derived angiopoietin-1 to its endothelial cell receptor TIE2 induces the release of the mesenchymal cell chemoattractant platelet-derived growth factor (PDGF) (30). Upon mesenchymal-endothelial cell contact, active transforming growth factor type β (TGF-β) is produced, which down-regulates endothelial cell proliferation and migration (31, 32) and induces the differentiation of mesenchymal cells into vascular smooth muscles (33) and deposition of a basement membrane matrix (34, 35). Continuous local activation of TGF-β also may be important for the structural maintenance of the vasculature (36). Polycystin 1 expressed in endothelium and smooth muscle cells normally may preserve vascular integrity during angiogenesis by stabilizing adhesion of these already differentiated cells to each other or to the extracellular matrix. In favor is the finding that mesenchymal recruitment and differentiation appear normal in Pkd1L/L mice, and the defect in vascular fragility is morphologically distinct and occurs at a later stage compared with that reported in TIE2-, PDGF-, TGF-β-, or angiopoeitin-1 knockout mice (37–41). Expression of polycystin 1 in subepithelial smooth muscles suggest a similar role of polycystin 1 in morphogenesis and structural stability of some ductal epithelium.
The reported apical junctional location of polycystin 1 in epithelial and endothelial cells also may be causally related to the s.c. edema and cyst formation observed in the Pkd1L/L mutant mice. Findings favoring this alternative (although not necessarily mutual) explanation is the detection of fluorescent dextran in the junctional regions of endothelia (Fig. 3F), and the occasional presence of nucleated red cells migrating across endothelial junctions in mutant (but not normal) embryos (Fig. 3B). It may be relevant that in the Pkd1L/L embryos and those described by Lu et al. (21) cyst formation first is observed in the proximal nephron, where tight junctions possess only one junctional strand (42). Recent work has elucidated crucial roles for intercellular junctions in cell growth, differentiation, polarity, and survival, processes that are abnormal in ADPKD (43). Interference with the formation of intercellular junctions induces the loss of cell polarity and growth regulation in Drosophila embryos homozygous for null mutants of the dlg gene, a tumor suppressor homologue of the junctional membrane-associated guanylate kinase (MAGUK) family member ZO1 (44). Also, vulval cells from Caenorhabditis elegans with mutation in LIN2, an invertebrate MAGUK family member, are not properly polarized and do not differentiate (45). The normal electron microscopy appearance of tight junctions in the Pkd1L/L embryos does not exclude a functional abnormality in vivo, because significant changes in permeability have been observed despite normally appearing cell–cell junctions (46, 47). Intercellular junctions are enriched in several classes of signaling proteins, including nonreceptor tyrosine kinases, protein kinase C, β catenin, small G proteins, and heterotrimeric G proteins, and recent data suggesting an interaction of polycystin 1 with heterotrimeric G proteins and the Wnt pathway have been published (48, 49).
Acknowledgments
We thank Dr. Mike Carroll for providing the pPNT plasmid, Dr. En Li for advice and assistance with blastocyst injections, and Drs. Mark Fishman and Scott Baldwin for helpful discussions. This work was supported by a PO1 Grant DK54711 from the National Institutes of Health. K.K. was supported by a fellowship award from the National Kidney Foundation.
Abbreviations
- ADPKD
autosomal dominant polycystic kidney disease
- E(n)
embryonic day
- WT
wild type
- ES
embryonic stem
- TSC2
tuberous sclerosis 2
- LRR
leucine-rich repeats
Note Added in Proof
Focal hemorrhage has now been reported in mice homozygous for a Pkd2 null allele (50).
Footnotes
Article published online before print: Proc. Natl. Acad. Sci. USA, 10.1073/pnas.040550097.
Article and publication date are at www.pnas.org/cgi/doi/10.1073/pnas.040550097
References
- 1.Dalgaard O Z. Acta Med Scand. 1957;328,Suppl.:1–255. [PubMed] [Google Scholar]
- 2.Grantham J J. Adv Intern Med. 1993;38:409–420. [PubMed] [Google Scholar]
- 3.Baert L. Kidney Int. 1978;13:519–525. doi: 10.1038/ki.1978.75. [DOI] [PubMed] [Google Scholar]
- 4.Gabow P A. N Eng J Med. 1993;329:332–342. doi: 10.1056/NEJM199307293290508. [DOI] [PubMed] [Google Scholar]
- 5.Huston J D, Torres V E, Sulivan P P, Offord K P, Wiebers D O. J Am Soc Nephrol. 1993;3:1871–1877. doi: 10.1681/ASN.V3121871. [DOI] [PubMed] [Google Scholar]
- 6.Ruggieri P M, Poulos N, Masaryk T J, Ross J S, Obuchowski N A, Awad I A, Braun W E, Nally J, Lewin J S, Modic M T. Radiology. 1994;191:33–39. doi: 10.1148/radiology.191.1.8134594. [DOI] [PubMed] [Google Scholar]
- 7.Schievink W I, Torres V E, Piepgras D G, Wiebers D O. J Am Soc Nephrol. 1992;3:88–95. doi: 10.1681/ASN.V3188. [DOI] [PubMed] [Google Scholar]
- 8.Zeier M, Fehrenbach P, Geberth S, Mohring K, Waldherr R, Ritz E. Kidney Int. 1992;42:1259–1265. doi: 10.1038/ki.1992.413. [DOI] [PubMed] [Google Scholar]
- 9.European Polycystic Kidney Disease Consortium. Cell. 1994;77:881–894. doi: 10.1016/0092-8674(94)90137-6. [DOI] [PubMed] [Google Scholar]
- 10.International Polycystic Kidney Disease Consortium. Cell. 1995;81:289–298. doi: 10.1016/0092-8674(95)90339-9. [DOI] [PubMed] [Google Scholar]
- 11.Mochizuki T, Wu G, Hayashi T, Xenophontos S L, Veldhuisen B, Saris J J, Reynolds D M, Cai Y, Gabow P A, Pierides A, et al. Science. 1996;272:1339–1342. doi: 10.1126/science.272.5266.1339. [DOI] [PubMed] [Google Scholar]
- 12.Qian F, Germino F J, Cai Y, Zhang X, Somlo S, Germino G G. Nat Genet. 1997;16:179–183. doi: 10.1038/ng0697-179. [DOI] [PubMed] [Google Scholar]
- 13.Daoust M C, Reynolds D M, Bichet D G, Somlo S. Genomics. 1995;25:733–736. doi: 10.1016/0888-7543(95)80020-m. [DOI] [PubMed] [Google Scholar]
- 14.Geng L, Segal Y, Peissel B, Deng N, Pei Y, Carone F, Rennke H G, Glucksmann-Kuis A M, Schneider M C, Ericsson M, et al. J Clin Invest. 1996;98:2674–2682. doi: 10.1172/JCI119090. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Griffin M D, Torres V E, Grande J P, Kumar R. Proc Assoc Am Physicians. 1996;3:185–197. [PubMed] [Google Scholar]
- 16.Palsson R, Sharma C, Kim K, McLaughlin M, Brown D, Arnaout M. Mol Med. 1996;2:702–711. [PMC free article] [PubMed] [Google Scholar]
- 17.Cai Y, Maeda Y, Cedzich A, Torres V E, Wu G, Hayashi T, Mochizuki T, Park J H, Witzgall R, Somlo S. J Biol Chem. 1999;274:28557–28565. doi: 10.1074/jbc.274.40.28557. [DOI] [PubMed] [Google Scholar]
- 18.Griffin M D, Torres V E, Grande J P, Kumar R. J Am Soc Nephrol. 1997;8:616–626. doi: 10.1681/ASN.V84616. [DOI] [PubMed] [Google Scholar]
- 19.Ibraghimov-Beskrovnaya O, Dackowski W R, Foggensteiner L, Coleman N, Thiru S, Petry L R, Burn T C, Connors T D, Van Raay T, Bradley J, et al. Proc Natl Acad Sci USA. 1997;94:6397–6402. doi: 10.1073/pnas.94.12.6397. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Peters D J, van de Wal A, Spruit L, Saris J J, Breuning M H, Bruijn J A, de Heer E. J Pathol. 1999;188:439–446. doi: 10.1002/(SICI)1096-9896(199908)188:4<439::AID-PATH367>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
- 21.Lu W, Peissel B, Babakhanlou H, Pavlova A, Geng L, Fan X, Larson C, Brent G, Zhou J. Nat Genet. 1997;17:179–181. doi: 10.1038/ng1097-179. [DOI] [PubMed] [Google Scholar]
- 22.Wu G, D'Agati V, Cai Y, Markowitz G, Park J H, Reynolds D M, Maeda Y, Le T C, Hou H, Jr, Kucherlapati R, et al. Cell. 1998;93:177–188. doi: 10.1016/s0092-8674(00)81570-6. [DOI] [PubMed] [Google Scholar]
- 23.Li E, Bestor T H, Jaenisch R. Cell. 1992;69:915–926. doi: 10.1016/0092-8674(92)90611-f. [DOI] [PubMed] [Google Scholar]
- 24.Zijlstra M, Li E, Sajjadi F, Subramani S, Jaenisch R. Nature (London) 1989;342:435–438. doi: 10.1038/342435a0. [DOI] [PubMed] [Google Scholar]
- 25.Coffin J D, Poole T J. Development (Cambridge, UK) 1988;102:735–748. doi: 10.1242/dev.102.4.735. [DOI] [PubMed] [Google Scholar]
- 26.Stewart P A, Wiley M J. Dev Biol. 1981;84:183–192. doi: 10.1016/0012-1606(81)90382-1. [DOI] [PubMed] [Google Scholar]
- 27.Grubb B R, Boucher R C. Phys Rev. 1999;79:193–214. doi: 10.1152/physrev.1999.79.1.S193. [DOI] [PubMed] [Google Scholar]
- 28.Pelletier J, Bruening W, Kashtan C E, Mauer S M, Manivel J C, Striegel J E, Houghton D C, Junien C, Habib R, Fouser L, et al. Cell. 1991;67:437–447. doi: 10.1016/0092-8674(91)90194-4. [DOI] [PubMed] [Google Scholar]
- 29.Lu W, Fan X, Basora N, Babakhanlou H, Law T, Rifai N, Harris P C, Perez-Atayde A R, Rennke H G, Zhou J. Nat Genet. 1999;21:160–161. doi: 10.1038/5944. [DOI] [PubMed] [Google Scholar]
- 30.Folkman J, D'Amore P A. Cell. 1996;87:1153–1155. doi: 10.1016/s0092-8674(00)81810-3. [DOI] [PubMed] [Google Scholar]
- 31.Orlidge A, D'Amore P A. J Cell Biol. 1987;105:1455–1462. doi: 10.1083/jcb.105.3.1455. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Sato Y, Rifkin D B. J Cell Biol. 1989;109:309–315. doi: 10.1083/jcb.109.1.309. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Hirschi K K, Rohovsky S A, D'Amore P A. J Cell Biol. 1998;141:805–814. doi: 10.1083/jcb.141.3.805. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Crocker D J, Murad T M, Geer J C. Exp Mol Pathol. 1970;13:51–65. doi: 10.1016/0014-4800(70)90084-5. [DOI] [PubMed] [Google Scholar]
- 35.Madri J A, Pratt B M, Tucker A M. J Cell Biol. 1988;106:1375–1384. doi: 10.1083/jcb.106.4.1375. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Chamley-Campbell J H, Campbell G R, Ross R. J Cell Biol. 1981;89:379–383. doi: 10.1083/jcb.89.2.379. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Dickson M C, Martin J S, Cousins F M, Kulkarni A B, Karlsson S, Akhurst R J. Development (Cambridge, UK) 1995;121:1845–1854. doi: 10.1242/dev.121.6.1845. [DOI] [PubMed] [Google Scholar]
- 38.Leveen P, Pekny M, Gebre-Medhin S, Swolin B, Larsson E, Betsholtz C. Genes Dev. 1994;8:1875–1887. doi: 10.1101/gad.8.16.1875. [DOI] [PubMed] [Google Scholar]
- 39.Suri C, Jones P F, Patan S, Bartunkova S, Maisonpierre P C, Davis S, Sato T N, Yancopoulos G D. Cell. 1996;87:1171–1180. doi: 10.1016/s0092-8674(00)81813-9. [DOI] [PubMed] [Google Scholar]
- 40.Soriano P. Genes Dev. 1994;8:1888–1896. doi: 10.1101/gad.8.16.1888. [DOI] [PubMed] [Google Scholar]
- 41.Vikkula M, Boon L M, Carraway K L, 3rd, Calvert J T, Diamonti A J, Goumnerov B, Pasyk K A, Marchuk D A, Warman M L, Cantley L C, et al. Cell. 1996;87:1181–1190. doi: 10.1016/s0092-8674(00)81814-0. [DOI] [PubMed] [Google Scholar]
- 42.Brown D, Orci L. J Electron Microsc Technol. 1988;9:145–170. doi: 10.1002/jemt.1060090204. [DOI] [PubMed] [Google Scholar]
- 43.Wilson P. Am J Physiol. 1997;272:F434–F442. doi: 10.1152/ajprenal.1997.272.4.F434. [DOI] [PubMed] [Google Scholar]
- 44.Woods D F, Bryant P J. Cell. 1991;66:451–464. doi: 10.1016/0092-8674(81)90009-x. [DOI] [PubMed] [Google Scholar]
- 45.Hoskins R, Hajnal A F, Harp S A, Kim S K. Development (Cambridge, UK) 1996;122:97–111. doi: 10.1242/dev.122.1.97. [DOI] [PubMed] [Google Scholar]
- 46.Wong V, Gumbiner B M. J Cell Biol. 1997;136:399–409. doi: 10.1083/jcb.136.2.399. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Papini E, Satin B, Norais N, de Bernard M, Telford J L, Rappuoli R, Montecucco C. J Clin Invest. 1998;102:813–820. doi: 10.1172/JCI2764. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Parnell S C, Magenheimer B S, Maser R L, Rankin C A, Smine A, Okamoto T, Calvet J P. Biochem Biophys Res Commun. 1998;251:625–631. doi: 10.1006/bbrc.1998.9514. [DOI] [PubMed] [Google Scholar]
- 49.Kim E, Arnould T, Sellin L K, Benzing T, Fan M J, Gruning W, Sokol S Y, Drummond I, Walz G. J Biol Chem. 1999;274:4947–4953. doi: 10.1074/jbc.274.8.4947. [DOI] [PubMed] [Google Scholar]
- 50.Wu G, Markowitz G S, Li L, D'Agati V D, Factor S M, Geng L, Tibara S, Tuchman J, Cai Y, Hoon Park J, et al. Nat Genet. 2000;24:75–78. doi: 10.1038/71724. [DOI] [PubMed] [Google Scholar]